Atai Life Sciences N.V.

NasdaqGM:ATAI Stock Report

Market Cap: US$226.5m

Atai Life Sciences Valuation

Is ATAI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ATAI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ATAI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ATAI's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ATAI?

Key metric: As ATAI barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ATAI. This is calculated by dividing ATAI's market cap by their current book value.
What is ATAI's PB Ratio?
PB Ratio2x
BookUS$116.30m
Market CapUS$226.53m

Price to Book Ratio vs Peers

How does ATAI's PB Ratio compare to its peers?

The above table shows the PB ratio for ATAI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average6.8x
AVIR Atea Pharmaceuticals
0.6x5.3%US$271.1m
TERN Terns Pharmaceuticals
0.7x-10.2%US$268.4m
RANI Rani Therapeutics Holdings
15.7x41.2%US$86.1m
MIST Milestone Pharmaceuticals
10x39.5%US$157.7m
ATAI Atai Life Sciences
2x42.8%US$226.5m

Price-To-Book vs Peers: ATAI is good value based on its Price-To-Book Ratio (2x) compared to the peer average (6.8x).

Price to Book Ratio vs Industry

How does ATAI's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

26 CompaniesPrice / BookEstimated GrowthMarket Cap
TLRY Tilray Brands
0.2x76.1%US$633.57m
CTXR Citius Pharmaceuticals
0.2x62.3%US$14.09m
RLMD Relmada Therapeutics
0.2x8.4%US$8.93m
AYTU Aytu BioPharma
0.2x76.8%US$7.28m
ATAI 2.0xIndustry Avg. 1.2xNo. of Companies26PB012345+
26 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ATAI is expensive based on its Price-To-Book Ratio (2x) compared to the US Pharmaceuticals industry average (1.2x).

Price to Book Ratio vs Fair Ratio

What is ATAI's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ATAI PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ATAI's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ATAI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.39
US$8.00
+475.5%
31.9%US$11.00US$5.00n/a4
Mar ’26US$1.72
US$8.00
+365.1%
31.9%US$11.00US$5.00n/a4
Feb ’26US$1.55
US$8.00
+416.1%
31.9%US$11.00US$5.00n/a4
Jan ’26US$1.33
US$8.00
+501.5%
31.9%US$11.00US$5.00n/a4
Dec ’25US$1.78
US$8.00
+349.4%
31.9%US$11.00US$5.00n/a4
Nov ’25US$1.08
US$9.25
+756.5%
43.5%US$15.00US$5.00n/a4
Oct ’25US$1.12
US$9.25
+725.9%
43.5%US$15.00US$5.00n/a4
Sep ’25US$1.30
US$9.25
+611.5%
43.5%US$15.00US$5.00n/a4
Aug ’25US$1.42
US$9.50
+569.0%
39.7%US$15.00US$6.00n/a4
Jul ’25US$1.35
US$11.80
+774.1%
48.4%US$21.00US$6.00n/a5
Jun ’25US$1.57
US$11.80
+651.6%
48.4%US$21.00US$6.00n/a5
May ’25US$2.05
US$11.80
+475.6%
48.4%US$21.00US$6.00n/a5
Apr ’25US$1.86
US$14.50
+679.6%
43.2%US$21.00US$6.00n/a4
Mar ’25US$2.13
US$12.62
+492.5%
53.5%US$21.00US$5.10US$1.725
Feb ’25US$1.81
US$12.62
+597.2%
53.5%US$21.00US$5.10US$1.555
Jan ’25US$1.41
US$12.62
+795.0%
53.5%US$21.00US$5.10US$1.335
Dec ’24US$1.12
US$12.35
+1,002.7%
50.1%US$21.00US$5.10US$1.786
Nov ’24US$1.19
US$12.16
+921.6%
47.3%US$21.00US$5.10US$1.087
Oct ’24US$1.29
US$12.16
+842.4%
47.3%US$21.00US$5.10US$1.127
Sep ’24US$1.54
US$11.51
+647.6%
49.0%US$21.00US$5.10US$1.308
Aug ’24US$2.05
US$12.26
+498.0%
40.9%US$21.00US$5.10US$1.4210
Jul ’24US$1.72
US$11.96
+595.6%
40.7%US$21.00US$5.10US$1.3511
Jun ’24US$1.72
US$11.96
+595.6%
40.7%US$21.00US$5.10US$1.5711
May ’24US$1.98
US$11.96
+504.2%
40.7%US$21.00US$5.10US$2.0511
Apr ’24US$1.81
US$11.88
+556.5%
39.1%US$21.00US$5.10US$1.8612
Mar ’24US$1.61
US$12.72
+689.9%
37.3%US$21.00US$5.10US$2.1312
Analyst Price Target
Consensus Narrative from 4 Analysts
US$8.00
Fair Value
82.6% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/19 01:46
End of Day Share Price 2025/03/19 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Atai Life Sciences N.V. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sumant Satchidanand KulkarniCanaccord Genuity
Charles DuncanCantor Fitzgerald & Co.
Neena Bitritto-GargCitigroup Inc